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ABSTRACT 
DNA methylation of promoter regions is a common molecular mechanism for inactivation of tumor suppressor 
genes that participates in carcinogenesis. Determining the methylation status of genes in cancer and their asso-
ciation with clinical features play an essential role in early diagnosis, prognosis and determine appropriate treat-
ment for patients. The purpose of the present study was to evaluate the methylation of tumor suppressor genes in 
patients with invasive ductal carcinoma (IDC). Furthermore, we evaluated the association between clinical pa-
rameters and DNA methylation as a biomarker in diagnostic IDC patients. The methylation-specific multiplex 
ligation dependent probe amplification (MS-MLPA) assay was used to analyze the methylation profile of 24 
genes in formalin-fixed paraffin embedded (FFPE) tissue samples from 75 patients with IDC. Each of the pa-
tients showed a distinctive methylation profile. We observed higher methylation in the RASSF1 (48 %), CDH13 
(44 %) and GSTP1 (36 %) genes. Some of the methylated genes were associated with clinical features. Methyla-
tion of GSTP1 (P=0.028) and RASSF1 (P=0.012) were related with lymph node metastasis. Methylation of 
GSTP1 (P=0.005) was associated with high histological grade. Moreover, concurrent methylation of GSTP1 and 
CDH13 was observed in IDC patients (p<0.001). Hierarchical cluster analysis based on the methylation profile 
revealed two main clusters of patients, the highly methylated cluster being significantly associated with high 
histological grade and lymph node metastasis. The results of this study indicate that the methylation status of 
RASSF1 and CDH13 and GSTP1 can be a prognostic marker to better management of IDC patients. 
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INTRODUCTION 
Breast cancer is a heterogeneous disease 
and the common tumor among women 
worldwide (Vo and Millis, 2012). Invasive 
breast carcinoma has been categorized by 
morphological criteria into invasive ductal 
carcinoma (IDC), invasive lobular carcinoma 
(ILC), and other less common subtypes. IDC 
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is the most common type and comprises 
about 80 % of the malignant form. ILC is the 
second most common type of invasive breast 
cancer after IDC. This type accounts for 
about 8-14 % (Hoque et al., 2009). 
Epigenetic alterations are the primary 
changes in cancer progression and play im-
portant roles in the pathogenesis of cancer. 
One of the most common epigenetic changes 
in cancers is methylation of CPG islands in 
gene promoter regions. Such changes con-
tribute to the process of tumorigenesis by 
silencing tumor suppressor genes (Delpu et 
al., 2013; Hatzimichael et al., 2014; Barrow 
and Michels, 2014). These genes play signif-
icant roles in the regulation of cell cycle, 
DNA repair, apoptosis and signal transduc-
tion (Esteller et al., 2001). 
Clinicopathological features routinely are 
used as strong predictive factors in the eval-
uation of breast cancer. These features in-
clude lymph node metastasis, histological 
grade and tumor size that indicate the malig-
nant potential of tumors (Rakha et al., 2008). 
Lymph node metastasis correlates with the 
risk of distant recurrence in patients. There is 
the most consistent prognostic factor used in 
adjuvant therapy decision making. For pa-
tients with non-metastatic lymph nodes, tu-
mor size is a predictive marker. Tumor grade 
does have significance for patients with non-
metastatic lymph node and borderline tumor 
sizes (Cianfrocca and Goldstein, 2004). 
Recent studies indicate that there are as-
sociations between methylation in some 
genes and clinicopathological parameters in 
breast cancer. Methylation in CDH13 is as-
sociated with tumor size (Xu et al., 2012). 
GSTP1 methylation is associated with tumor 
size and nodal metastasis (Arai et al., 2006). 
Furthermore, an association of RARB pro-
moter methylation with lymph node metasta-
sis has been reported (Marzese et al., 2012). 
The identification of methylated genes and 
their relationship to clinical features can con-
tribute to the prognosis and early detection 
of tumor.  
In recent years, the role of aberrant 
methylation in the development of invasive 
breast cancer has been the subject of various 
researches yielding controversial outcomes 
(Parrella et al., 2004; Lewis et al., 2005). 
Previous studies have pointed that methyla-
tion profiles are specific for each type of 
human cancer and different in various eth-
nicities (Esteller et al., 2001). In spite of in-
tensive studies, the pathogenesis of IDC has 
not been completely revealed (Parrella et al., 
2004; Lewis et al., 2005). A recent study has 
pointed to the presence of a unique methyla-
tion profile in IDC (Marzese et al., 2012). 
However, this profile and its relation to clin-
ical features are not clear yet (Xu et al., 
2012; Marzese et al., 2012) because most of 
previous studies have investigated methyla-
tion in only a few genes for pure IDC cases 
(Ramalho et al., 2014; Mirza et al., 2007). 
Several techniques exist to assess gene 
methylation status. However, most of them 
are able to examine only one gene at a time 
(Pang et al., 2013). The MS-MLPA is a new, 
relatively simple and sensitive technique for 
detecting the methylation status of multiple 
genes in a single reaction. This method can 
be used to determine the profile of methylat-
ed genes in different types of cancer (Nygren 
et al., 2005). 
The purpose of this research was im-
provement of our understanding of promoter 
methylation of tumor suppressor genes in 
IDC samples using MS-MLPA assay. Fur-
thermore, we evaluated the association be-
tween clinical parameters and methylation of 
tumor suppressor genes in order to a better 
understanding of the pathogenesis and heter-
ogeneity of breast carcinoma. 
 
MATERIALS AND METHODS 
 
Patients and tissue samples 
In this study, formalin-fixed paraffin em-
bedded (FFPE) samples from 80 patients 
with breast carcinoma were acquired from 
the archive of the pathology laboratories in 
the Tabriz (Iran). Furthermore, 10 normal 
tissues were considered as control samples. 
Previously, written informed approval was 
acquired from all patients. All samples were 
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reviewed by a pathologist to confirm the di-
agnosis, according to World Health Organi-
zation criteria. Tumors were histologically 
graded from 1 to 3 according to the Notting-
ham Histologic score (Elston and Ellis, 
2002). To evaluate a group of patients with 
similar clinical features, we selected only 
pure invasive ductal carcinomas (IDCs) 
(n=75) from the 80 obtained samples. 
Pathological files were reviewed to rec-
ord clinicopathological parameters such as 
age, grade, lymph node status and tumor size 
(Table 1). The mean age of these patients 
was 48 years (range 28 to 68 years). The 
samples of normal breast were retrieved 
from patients that had undergone surgery for 
diagnosis. Breast cancer in these samples 
was excluded by the pathologist. Use of 
FFPE samples for this research was ap-
proved by the ethics boards of the Hematol-
ogy and Oncology Research Center, Tabriz 
University of Medical Sciences. 
 
Table 1: Clinical and pathological characteristics 
of samples with IDC (N=75) 
Frequency 
(  %) 
Number Characteristics 
 75 Total patients 
  Lymph node  
metastasis 
42.7 32 Negative 
57.3 43 Positive 
  Histological grade 
54.7 41 1-2 
45.3 34 3 
  Tumor size (cm) 
52 39 ≥ 3 
48 36 < 3 
  Age (years)* 
45.3 34 ≥ 50 
54.7 41 < 50 
 
 
DNA extraction 
Three to four sections (5-8 µm thick) 
were acquired from each paraffin block. To 
remove paraffin, the samples were incubated 
at 75 °C for 15 minutes and washed with Xy-
lene (3×10 minutes). DNA was extracted us-
ing QIAamp DNA FFPE kit (Qiagen) ac-
cording to the manufacturer’s guidelines. 
The quantity and purity of DNA samples 
were evaluated by NanoDrop 1000 spectro-
photometer (Thermo Scientific, DE, USA).  
 
MS-MLPA assay 
DNA methylation was assessed by MS-
MLPA using the ME001-C2 tumor suppres-
sor kit (MRC-Holland, Amsterdam, and The 
Netherlands). The ME001-C2 kit contains 26 
different probes for 24 tumor suppressor 
genes. These genes are frequently inactivated 
by methylation in tumors, but are unmethyl-
ated in healthy subjects. In addition, the kit 
includes 15 reference probes, which remain 
uncut after digestion by HhaI restriction en-
zyme. Information about the length of the 
probes, genes locus and sequence with HhaI 
site can be found at MRC-Holland website. 
The MS-MLPA method is based on the 
probes to determine methylation quantifica-
tion. The probes bind to the target sequences 
which contain a cleavage location for the 
methylation-sensitive HhaI enzyme. Proce-
dures were performed according to the kit 
manufacturer's instructions with slight modi-
fication. After DNA denaturation and probe 
hybridization, each of the samples is divided 
into two microtubes. One of them is incubat-
ed with the HhaI enzyme. If the sample 
DNA is unmethylated, hybrids of probe and 
DNA will be digested by HhaI and will not 
generate a signal in capillary electrophoresis 
analysis. However, methylated DNA is pre-
vented from being digested by enzyme. As a 
result, the ligated probes will be amplified by 
PCR and the signal will be generated. 
PCR products were separated by the ca-
pillary electrophoresis sequencer (ABI 310; 
Applied Biosystems, Foster City, CA, USA) 
and the results were analyzed by GeneMark-
er software (version 2.6, Soft Genetics, State 
College, PA). Based on previous studies, a 
methylation of gene was considered as posi-
tive when the methylation ratio was higher 
than 0.15 (Moelans et al., 2011). 
 
Statistical analysis 
The K2 test was used to examine the re-
lations between methylation status of CPG 
islands and clinicopathological variables 
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(age, grade, tumor size and lymph node me-
tastasis). Associations with P-value <0.05 
were considered as significant. Statistical 
analyses were performed using SPSS version 
22 software. Furthermore, hierarchical clus-
tering with Manhattan distance and complete 
linkage was performed using MATLAB 
(R2013b) software. 
 
RESULTS 
Methylation status by MS-MLPA 
Analysis of tumor suppressor genes using 
MS-MLPA, indicated that all 24 genes were 
unmethylated in the normal samples (n = 10) 
while, methylation patterns in all the IDC 
samples were manifestly variable. Each of 
the patients showed a distinctive methylation 
profile. In 21 genes, methylation was ob-
served in at least one tumor tissue. 
The most frequently methylated genes 
were RASSF1 (48 %), CDH13 (44 %) and 
GSTP1 (36 %). Methylation was not ob-
served in MLH1, VHL, CD44 and CHFR 
gene promoters in IDC patients. However, in 
two tumor samples, 9 genes were detected as 
methylated. Frequency distribution of DNA 
methylation for each of 26 analyzed genes is 
displayed in (Figure 1) and to better under-
stand how values are spaced, methylation 
levels of the nine significant genes are 
shown as box plot (Figure 2). The ME001-
C2 kit contains two different CpG islands for 
RASSF1 gene (328 bp and 382 bp). One of 
them was methylated in 48 % of IDC pa-
tients and the other in 36 %. 
 
Figure 1: Frequency distribution of DNA methylation for each of 26 analyzed CpG islands among  
75 IDCs 
 
Figure 2: Methylation levels of the nine significant genes showed as box plot
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Association between DNA methylation and 
clinicopathological parameters 
In the current study, we investigated the 
association between three genes with most 
frequently methylation (RASSF1, CDH13 
and GSTP1) and clinicopathological parame-
ters of the patients. Furthermore, we ana-
lyzed IDC patients for concurrent methyla-
tion of these genes. 
Methylation of RASSF1 (P= 0.012) and 
GSTP1 (P=0.028) were associated with 
lymph node metastasis. Methylation of 
GSTP1 (P=0.005) showed a statistically sig-
nificant association with high histological 
grade. However, no statistically considerable 
association was found between CDH13 
methylation and clinicopathological features. 
In addition, a significant correlation between 
patient's age and tumor size with methylation 
status was not observed (Table 2). Moreover, 
methylation status of GSTP1 was associated 
with methylation of CDH13 (Figure 3) but, 
no statistically considerable association was 
found between methylation of other genes. 
 
Table 2: Association between the methylation 
status and the clinicopathological characteristics 
of IDC patients 
GSTP1 CDH13 RASSF1  
M 
(27) 
U 
(48) 
M 
(33) 
U 
(42) 
M 
(36) 
U 
(39) 
N=75 
      Lymph 
node 
7 25 14 18 10 22 Negative 
(32) 
20 23 19 24 26 17 Positive 
(43) 
0.0280.97 0.012 P-Value 
      Grade 
9 32 17 24 22 19 1-2  (41) 
18 16 16 18 14 20 3   (34) 
0.0050.627 0.281 P-Value 
      Tumor 
size(cm) 
15 24 13 26 18 21 ≥ 3  (39) 
12 24 20 16 18 18 < 3  (36) 
0.644 0.053 0.739 P-Value 
      Age 
(years) 
9 25 15 19 13 21 ≥ 50  (34) 
18 23 18 23 23 18 < 50  (41) 
0.117 0.985 0.123 P-Value 
U: Unmethylated, M: Methylated 
 
 
 
Figure 3: Concurrent methylation of CDH13 and 
GSTP1 in IDC patients (P < 0.001) 
 
 
Cluster analysis 
Unsupervised hierarchical clustering was 
applied to classify cases with correlated 
methylation profiles and genes with correlat-
ed methylation patterns. For this analysis, to 
decrease the effect of genes that were rarely 
or never methylated, we selected genes that 
methylated in more than 10 % of the IDC 
patients. This analysis based on the methyla-
tion profile revealed two main clusters of 
patients; cluster 1 samples were character-
ized by RASSF1A, CDH13 and GSTP1 
methylation but cluster 2 samples showed 
APC and RASSF1 methylation (Figure 4). 
Cluster 1 being significantly associated with 
high histological grade (P=0.005) and lymph 
node metastasis (P=0.028) compared with 
cluster 2. 
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Figure 4: Unsupervised hierarchical cluster 
analysis of the methylation profile of 75 IDCs 
using the information from 9 genes.  
 
DISCUSSION 
IDC is the most common type of malig-
nant breast cancer. Identification of the mo-
lecular biological mechanisms in IDC con-
tributes to a well understanding of the dis-
ease, early diagnosis and determining the 
appropriate treatment strategies. Aberrant 
DNA methylation is an important epigenetic 
alteration that occurs in the early stages of 
human tumors, including breast cancer 
(Brooks et al., 2009). 
The objective of the present study was to 
assess the methylation in promoter regions of 
24 tumor suppressor genes on samples pre-
pared from 75 IDC subjects and 10 controls 
using MS-MLPA. In addition, we investigat-
ed for any associations between the methyla-
tion status of gene promoters and the clini-
copathological features for higher methylat-
ed genes. 
The most frequently methylated genes in 
our study were RASSF1, CDH13 and 
GSTP1. However, methylation was not ob-
served in MLH1, VHL, CD44 and CHFR 
genes. Previous studies have demonstrated 
that RASFF1 and APC are the most fre-
quently methylated genes in IDC (Marzese et 
al., 2012). 
RASSF1 is a tumor suppressor gene that 
is involved in apoptotic pathways, signal 
transduction and regulates cell proliferation. 
Methylation of RASSF1 has been commonly 
observed in a variety of human tumor types 
(Wei et al., 2013; Dammann et al., 2005). 
The highest frequency of RASSF1 meth-
ylation (70 % and 71.4 %) has been reported 
in IDC patients from India and Argentina 
(Marzese et al., 2012; Brooks et al., 2009). 
The methylation frequency of RASSF1 gene 
(48 %) obtained in our study is close to the 
results previously reported by other re-
searchers for Iranian IDC patients (50 %) 
(Rasti et al., 2009). Possible reasons behind 
these differences can be included ethnic di-
versity and tumor tissue heterogeneity. 
Many studies have reported that the most 
methylated gene in breast cancer is RASSF1 
(Brooks et al., 2009; Cho et al., 2012). Al-
though it may be silenced by deletion or 
point mutations, promoter hypermethylation 
is a common mechanism in loss of function 
of RASSF1 in cancer (Yoon et al., 2001). 
Therefore, this can be a reason for the high-
er-frequency of methylation in RASSF1 rela-
tive to other genes in breast tumors. 
In this study methylation of RASSF1 
showed a statistically significant relationship 
with lymph node metastasis that has been 
reported by previous studies (Dammann et 
al., 2005). This result seems to be a useful 
prognostic biomarker in breast cancer. 
CDH13 (H-Catherine) was the second 
most methylated gene in our results (44 % of 
cases). CDH13 is a cell adhesion protein and 
decreased expression of this gene plays an 
essential role in tumor metastasis. Methyla-
tion in CHD13 has been reported in several 
cancers including invasive bladder, ovarian 
and breast cancers (Lin et al., 2014; Bol et 
al., 2010). It has been found to be methylated 
in 33 % of breast cancer patients (Xiang et 
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al., 2013). But, CDH13 methylation has not 
been extensively examined in IDC. Xu et al. 
(2012) indicated that CDH13 methylation in 
breast cancer was associated with tumor size, 
while in our study no statistically association 
was found between CDH13 methylation and 
clinicopathological features. 
GSTP1 was the third most frequently 
methylated gene (36 % of cases). The meth-
ylation rate of GSTP1 remains controversial 
in IDCs because of the variation of reported 
frequencies ranging from 0 to 39 % (Tserga 
et al., 2012). 
Previous studies indicated that GSTP1 
methylation is more likely a late event in the 
pathogenesis of breast tumors (Arai et al., 
2006). Recently, GSTP1 methylation was 
shown to be significantly associated with 
increased age, tumor size and lymph node 
metastasis (Arai et al., 2006; Xiang et al., 
2013; Shinozaki et al., 2005). In this study, 
GSTP1 methylation exhibited a trend toward 
relationship with lymph node metastasis and 
increasing IDC grade.  
A recent study has shown concurrent 
methylation of GSTP1 and RASSF1 in IDC 
patients (Sharma et al., 2009), while in our 
study no statistically association was found 
between these genes. Only, GSTP1 methyla-
tion was significantly associated with 
CDH13 methylation. This association sug-
gests that these genes do not appear to be 
methylated alone. Some tumors exhibit con-
current methylation of several genes, a phe-
nomenon known as the CpG island methyla-
tor phenotype (CIMP), which is tumor type 
specific. Moreover, in invasive breast can-
cers, a breast CIMP (B-CIMP) has been de-
scribed and associated with clinical outcome. 
However the molecular mechanisms generat-
ing the concurrent methylation are still un-
known (Fang et al., 2011). But, there is a hy-
pothesis that overexpression of DNA me-
thyltransferase (DNMT) causes methylation 
of specific clusters of genes in breast cancer 
(Giordano and Normanno, 2009). 
Hierarchical cluster analysis based on the 
methylation profile revealed two main clus-
ters of patients, the highly methylated cluster 
being significantly associated with high his-
tological grade and lymph node metastasis. 
Our results demonstrated that methylation 
statuses of genes could be used to classify 
IDC patients into the same groups and in 
consequence they receive the same treat-
ment. 
In order to compare MS-MLPA with 
other methods, some of earlier studies were 
investigated. Several studies using methyla-
tion-specific polymerase chain reaction 
(MSP) method have demonstrated methyla-
tion of RASSF1A (51 %) (Rasti et al., 2009), 
GSTP1 (34.4 %) (Saxena et al., 2012), APC 
(36 %) (Jin et al., 2001) and CDH13 (33 %) 
(Toyooka et al., 2001) in breast cancer sam-
ples. Furthermore, Feng and colleagues 
(2007) analyzed the methylation of multiple 
genes in breast cancer using bisulfite pyrose-
quencing and found that RASSF1 was meth-
ylated in 58 % of breast tumors, CDH13 in 
44 % and RARB in 17 %. Also, APC and 
RASSF1, using quantitative MSP method, 
have been found to be methylated in 42 % 
and 48.6 % of breast cancer samples, respec-
tively (Lee et al., 2004; Stuopelyte et al., 
2013). These results are almost similar to the 
findings of our study that show the concord-
ance between MS-MLPA and other methods 
to assess gene methylation status. Also, sev-
eral studies have compared MS–MLPA with 
MSP or pyrosequencing and showed a good 
concordance between MS–MLPA and these 
methods (Furlan et al., 2013). Roessler and 
colleagues (2015) recently studied genome-
wide DNA methylation patterns for breast 
cancer subtypes using the Infinium Human 
Methylation 450k (HM450k) BeadChip. In 
general, this method is a proper tool to per-
form large-scale DNA methylation profiling. 
But, HM450k analysis and interpretation are 
more complex than initially thought (De-
deurwaerder et al., 2014). Moreover, no 
standardized statistical guideline for the 
evaluation of HM450K BeadChip data has 
been established (Roessler et al., 2015). But 
MS-MLPA is a relatively simple and sensi-
tive technique for detecting the methylation 
status (Nygren et al., 2005). Also, Trabelsi 
EXCLI Journal 2016;15:11-20 – ISSN 1611-2156 
Received: July 24, 2015, accepted: December 05, 2015, published: January 11, 2016 
 
 
18 
and colleagues (2015) have demonstrated a 
concordance between MS–MLPA and 
HM450k BeadChip. 
Comparison of the results obtained from 
the present study with previous reports 
showed that the methylation statuses of 
genes and reported frequencies are highly 
variable. These may be due to differences in 
the populations and ethnicities that were 
studied. More reasons for this variation are 
differences in sample size, methylation as-
sessment techniques and statistical methods 
in each study. 
In present study no follow-up data about 
the IDC patients are available to define 
whether DNA methylation is related with 
outcome in IDC patients. Therefore, this re-
lationship should be validated in further re-
searches in large groups of patients with fol-
low-up to improve invasive breast carcinoma 
management.  
 
CONCLUSION 
The present findings indicate that meth-
ylation of RASSF1, CDH13 and GSTP1 can 
be used as prognostic factors to better man-
agement of IDC patients. However, these 
findings should be approved by further stud-
ies prior to use as epigenetic markers on 
IDC.  
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